Prosecution Insights
Last updated: July 05, 2026
Application No. 19/264,028

CATHETER SYSTEMS

Final Rejection §DOUBLEPATENT§DP
Filed
Jul 09, 2025
Priority
Sep 02, 2010 — continuation of 9289606 +4 more
Examiner
ZINK, AMANDA L
Art Unit
3794
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Abbott Laboratories
OA Round
2 (Final)
85%
Grant Probability
Favorable
3-4
OA Rounds
2y 3m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allowance Rate
573 granted / 673 resolved
+15.1% vs TC avg
Minimal +3% lift
Without
With
+2.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
8 currently pending
Career history
690
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
55.4%
+15.4% vs TC avg
§102
13.3%
-26.7% vs TC avg
§112
1.7%
-38.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 673 resolved cases

Office Action

§DOUBLEPATENT §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Response to Amendment Receipt is acknowledged of amendment filed 11/20/2025. Claims 1-21 are pending and an action on the merits is as follows. The examiner notes that the current application claims priority to 09/20/2010. As such, examination of the claimed invention reviewed with prior art found prior to the stated date. Specification The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-21 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-21 of U.S. Patent No. 9,289,606. Although the claims at issue are not identical, they are not patentably distinct from each other because both the present application and the previously patented invention are directed towards an electroporation system which has an electrode assembly which comprises a plurality of electrodes that are selectively energized in a bipolar fashion to deliver electroporation energy between two arrays or loops that are separately arranged. Claims 1-21 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-19 of U.S. Patent No. 11,000,684. Although the claims at issue are not identical, they are not patentably distinct from each other because both the present application and the previously patented invention are directed towards an electroporation system which has an electrode assembly which comprises a plurality of electrodes that are selectively energized in a bipolar fashion to deliver electroporation energy between two arrays or loops that are separately arranged. Claims 1-21 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-18 of U.S. Patent No. 12,383,736. Although the claims at issue are not identical, they are not patentably distinct from each other because both the present application and the previously patented invention are directed towards an electroporation system which has an electrode assembly which comprises a plurality of electrodes that are selectively energized in a bipolar fashion to deliver electroporation energy between two arrays or loops that are separately arranged. Response to Arguments Applicant’s arguments, see pages 9-14 of applicant's remarks, filed 11/20/2025, with respect to claims 1-20 have been fully considered and are persuasive. The 103 rejection of claims 1-20 has been withdrawn. The examiner notes that the current application has a priority date of 09/02/2010. While electroporation devices are known in the art, the current claimed invention is not found in the prior art, before the priority date of 2010. A further review of the claimed limitations results in maintaining the issued double patenting rejection issued in the Non-Final rejection dated 08/22/2025. As discussed above, both the present application and the previously patented invention are directed towards bipolar electroporation that is selectively energized between selected electrodes. The nonstatutory double patenting rejection of claims 1-21 is maintained. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMANDA L ZINK whose telephone number is (571)270-7103. The examiner can normally be reached Monday-Friday 7-12 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joanne Hoffman can be reached at (303)297-4276. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.L.Z/ Examiner, Art Unit 3794 /MICHAEL F PEFFLEY/ Primary Examiner, Art Unit 3794
Read full office action

Prosecution Timeline

Jul 09, 2025
Application Filed
Aug 22, 2025
Non-Final Rejection mailed — §DOUBLEPATENT, §DP
Nov 05, 2025
Interview Requested
Nov 12, 2025
Applicant Interview (Telephonic)
Nov 12, 2025
Examiner Interview Summary
Nov 20, 2025
Response Filed
May 05, 2026
Final Rejection mailed — §DOUBLEPATENT, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12653606
APPARATUS AND METHODS FOR TUMOR ABLATION
1y 6m to grant Granted Jun 16, 2026
Patent 12623067
Electroporation Delivery Systems and Methods of Using Electroporation Delivery Systems
3y 11m to grant Granted May 12, 2026
Patent 12575879
METHODS, APPARATUSES, AND SYSTEMS FOR THE TREATMENT OF PULMONARY DISORDERS
3y 9m to grant Granted Mar 17, 2026
Patent 12558170
GRAPHICAL USER INTERFACES FOR ABLATION SYSTEMS
4y 6m to grant Granted Feb 24, 2026
Patent 12558157
APPARATUS AND METHODS FOR PULSED FIELD ABLATION INCLUDING COMPRESSIBLE ELECTRODES
1y 2m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
85%
Grant Probability
88%
With Interview (+2.9%)
3y 3m (~2y 3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 673 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month